Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 403,364 shares of CYTK, which is worth approximately $20.4 Million. The most recent transaction as insider was on Mar 02, 2022, when has been sold 15,866 shares (Common Stock) at a price of $37.63 per share, resulting in proceeds of $597,038. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 403K

1.49% 3M change

8.62% 12M change

Total Value Held $20.4 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 02 2022	SELL Payment of exercise price or tax liability	$597,038 $37.63 p/Share	15,866 Reduced 4.36%	347,923 Common Stock
Mar 02 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.21%	442,923 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	85,000 Added 16.41%	432,923 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$400,140 $35.32 p/Share	11,329 Reduced 3.02%	363,789 Common Stock
Feb 16 2022	SELL Open market or private sale	$365,000 $36.5 p/Share	10,000 Reduced 2.7%	360,644 Common Stock
Feb 16 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.63%	370,644 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	14,474 Added 3.72%	375,118 Common Stock
Feb 07 2022	SELL Open market or private sale	$338,600 $33.86 p/Share	10,000 Reduced 2.7%	360,644 Common Stock
Feb 07 2022	BUY Exercise of conversion of derivative security	$79,600 $7.96 p/Share	10,000 Added 2.63%	370,644 Common Stock
Nov 12 2021	SELL Open market or private sale	$164,187 $39.63 p/Share	4,143 Reduced 1.14%	360,063 Common Stock
Nov 12 2021	BUY Exercise of conversion of derivative security	$24,858 $6.0 p/Share	4,143 Added 1.12%	364,206 Common Stock
Oct 29 2021	SELL Open market or private sale	$179,000 $35.8 p/Share	5,000 Reduced 1.37%	360,063 Common Stock
Oct 29 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.35%	365,063 Common Stock
Oct 14 2021	SELL Open market or private sale	$188,700 $37.74 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Oct 14 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.36%	362,563 Common Stock
Sep 30 2021	SELL Open market or private sale	$170,050 $34.01 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Sep 30 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.36%	362,563 Common Stock
Sep 15 2021	SELL Open market or private sale	$163,300 $32.66 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Sep 15 2021	BUY Exercise of conversion of derivative security	$30,750 $6.15 p/Share	5,000 Added 1.36%	361,628 Common Stock
Sep 02 2021	SELL Open market or private sale	$165,600 $33.12 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Sep 02 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
Aug 18 2021	SELL Open market or private sale	$155,700 $31.14 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Aug 18 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
Aug 05 2021	SELL Open market or private sale	$145,600 $29.12 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Aug 05 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account